Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

Oliver Schnell, Tadej Battelino, Richard Bergenstal, Matthias Blüher, Michael Böhm, Frank Brosius, Richard D. Carr, Antonio Ceriello, Thomas Forst, Francesco Giorgino, Bruno Guerci, Hiddo J.L. Heerspink, Baruch Itzhak, Linong Ji, Mikhail Kosiborod, Nebojša Lalić, Michael Lehrke, Nikolaus Marx, Michael Nauck, Helena W. RodbardGiuseppe M.C. Rosano, Peter Rossing, Lars Rydén, Francesca Santilli, Petra Maria Schumm-Draeger, Per Olav Vandvik, Tina Vilsbøll, Christoph Wanner, Carol Wysham, Eberhard Standl

Research output: Contribution to journalComment/debatepeer-review

Abstract

The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year’s focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1–5, and STEP 1–5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed. Trial registration The 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10–11, 2022 (http://www.cvot.org).

Original languageEnglish (US)
Article number50
JournalCardiovascular Diabetology
Volume21
Issue number1
DOIs
StatePublished - Dec 2022

Keywords

  • Cardiovascular disease
  • Chronic kidney disease
  • Diabetes
  • GLP-1 receptor agonist
  • Heart failure
  • Living guidelines
  • Mineralocorticoid receptor antagonist
  • Obesity
  • SGLT2 inhibitor
  • Tirzepatide

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes'. Together they form a unique fingerprint.

Cite this